Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia


Simsek E. T. , Eskazan A. E. , Cengiz M., Ar M. C. , Ekizoglu S., Salihoglu A., ...More

JOURNAL OF CLINICAL PATHOLOGY, vol.69, no.9, pp.810-816, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 9
  • Publication Date: 2016
  • Doi Number: 10.1136/jclinpath-2015-203320
  • Title of Journal : JOURNAL OF CLINICAL PATHOLOGY
  • Page Numbers: pp.810-816

Abstract

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.